Create Account | Forget Password?               
Home Asthma Cancer Cardiology Diabetes Neurology Nutrition Pediatrics OB / GYN General
Health Center
Ads & Resources
Comprehensive Health Directory
Manage Patient Records

 
Home » Cancer
Cancer Videos  « Go Back

'Cancer Research' Has Published a Paper on the Activity of MM-121, an ErbB3 Inhibitor, in Ligand-dependent Tumors

Posted By: Anonymous | Posted On: Mar 15,2010 18:30 pm | View: 15 Dana-Farber Cancer Institute, Massachusetts General Hospital Cancer Center, Dana-Farber/Harvard Cancer Center, Cell Signaling Technology, Harvard Medical School and Merrimack Pharmaceuticals collaborated on the MM-121 research. Researchers looked at MM-121 in combination with Erbitux to study efficacy in preclinical cancer models resistant to other targeted therapies. Read More: http://www.prweb.com/releases/2010/03/prweb3733734.htm



 
Other Health Sources
About Us |  Contact Us |  Asthma |  Cancer |  Cardiology |  Diabetes |  Neurology |  Diet & Nutrition |  Pediatrics |  OB/GYN |  General
Copyright © 2008-2012, DoctorsOutlook.com, All Rights Reserved.
Disclaimer: Issuers of the submissions/postings are solely responsible for the content of their submissions. Doctorsoutlook.com can't be held liable for the contents of these submissions. In case any submission damages your benefits or violate your rights in any way, please contact us and we'll remove it immediately.